Pioneering Treatments for NASH: Madrigal Pharmaceuticals NASDAQ:MDGL is leading the charge in developing treatments for non-alcoholic steatohepatitis (NASH). Its drug, Rezdiffra, is the only approved treatment for metabolic-associated steatohepatitis (MASH). With ongoing research to expand its indications, Madrigal is well-positioned in a market projected to be...
The Food and Drug Administration (FDA) has granted approval to Madrigal Pharmaceuticals' ( NASDAQ:MDGL ) groundbreaking drug, Rezdiffra, as the first-ever treatment for nonalcoholic steatohepatitis (NASH) liver disease. This approval marks a significant breakthrough in the medical landscape, providing hope for millions worldwide battling this potentially deadly...
Setup: PowerPlay VCP: 6W 19/5 3T RS: 99 The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the...
MDGL up big on FDA fast track on positive results. Overbought and overdone here. We should correct under $200 in coming days
Over the last three days, Tickeron A.I.dvisor has detected that MDGL's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring...
Over the last three days, Tickeron A.I.dvisor has detected that MDGL's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring...